Magenta Therapeutics Stock Forecast, Price & News

Magenta Therapeutics (NASDAQ:MGTA) Frequently Asked Questions

Is Magenta Therapeutics a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Magenta Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Magenta Therapeutics stock.
View analyst ratings for Magenta Therapeutics or view top-rated stocks.

How has Magenta Therapeutics' stock been impacted by COVID-19?

Magenta Therapeutics' stock was trading at $9.16 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MGTA stock has decreased by 54.0% and is now trading at $4.21.
View which stocks have been most impacted by COVID-19.

When is Magenta Therapeutics' next earnings date?

Magenta Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, March 2nd 2022.
View our earnings forecast for Magenta Therapeutics.

How were Magenta Therapeutics' earnings last quarter?

Magenta Therapeutics, Inc. (NASDAQ:MGTA) posted its quarterly earnings results on Thursday, November, 4th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.03.
View Magenta Therapeutics' earnings history.

What price target have analysts set for MGTA?

6 brokers have issued twelve-month target prices for Magenta Therapeutics' shares. Their forecasts range from $7.00 to $20.00. On average, they expect Magenta Therapeutics' share price to reach $15.00 in the next year. This suggests a possible upside of 256.3% from the stock's current price.
View analysts' price targets for Magenta Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Magenta Therapeutics' key executives?

Magenta Therapeutics' management team includes the following people:

• Jason Gardner, President, Chief Executive Officer & Director
• Stephen Frank Mahoney, COO, CFO, Treasurer & Chief Accounting Officer
• Lisa M. Olson, Chief Scientific Officer & Head-Research
• David Nichols, Chief Technical Officer
• Jeffrey S. Humphrey, Chief Medical Officer

What is Jason Gardner's approval rating as Magenta Therapeutics' CEO?

3 employees have rated Magenta Therapeutics CEO Jason Gardner on Glassdoor.com. Jason Gardner has an approval rating of 60% among Magenta Therapeutics' employees. This puts Jason Gardner in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Magenta Therapeutics' key competitors?

Some companies that are related to Magenta Therapeutics include Crinetics Pharmaceuticals (CRNX), Zealand Pharma A/S (ZEAL), BELLUS Health (BLUSF), Day One Biopharmaceuticals (DAWN), Atai Life Sciences (ATAI), AnaptysBio (ANAB), Northwest Biotherapeutics (NWBO), Nurix Therapeutics (NRIX), uniQure (QURE), Heron Therapeutics (HRTX), Kura Oncology (KURA), ADVANZ PHARMA (CXRXF), GH Research (GHRS), Gossamer Bio (GOSS) and Syndax Pharmaceuticals (SNDX).
View all of MGTA's competitors.

What other stocks do shareholders of Magenta Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Magenta Therapeutics investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Vaxart (VXRT), ADMA Biologics (ADMA), NVIDIA (NVDA), Pfizer (PFE), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD), Amarin (AMRN) and CRISPR Therapeutics (CRSP).

When did Magenta Therapeutics IPO?

(MGTA) raised $100 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Magenta Therapeutics' stock symbol?

Magenta Therapeutics trades on the NASDAQ under the ticker symbol "MGTA."

Who are Magenta Therapeutics' major shareholders?

Magenta Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Aries Wealth Management (0.07%). Company insiders that own Magenta Therapeutics stock include Bruce Booth and Kristen Stants.
View institutional ownership trends for Magenta Therapeutics.

Which major investors are buying Magenta Therapeutics stock?

MGTA stock was bought by a variety of institutional investors in the last quarter, including Aries Wealth Management.
View insider buying and selling activity for Magenta Therapeutics or or view top insider-buying stocks.

How do I buy shares of Magenta Therapeutics?

Shares of MGTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Magenta Therapeutics' stock price today?

One share of MGTA stock can currently be purchased for approximately $4.21.

How much money does Magenta Therapeutics make?

Magenta Therapeutics has a market capitalization of $247.45 million. The company earns $-74.94 million in net income (profit) each year or ($1.36) on an earnings per share basis.

How many employees does Magenta Therapeutics have?

Magenta Therapeutics employs 69 workers across the globe.

What is Magenta Therapeutics' official website?

The official website for Magenta Therapeutics is www.magentatx.com.

Where are Magenta Therapeutics' headquarters?

Magenta Therapeutics is headquartered at 100 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139.

How can I contact Magenta Therapeutics?

Magenta Therapeutics' mailing address is 100 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The company can be reached via phone at (857) 242-0170 or via email at [email protected].